First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)

Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Gaku, Asahina, Hajime, Honjo, Osamu, Sumi, Toshiyuki, Nakamura, Atsushi, Ito, Kenichiro, Kikuchi, Hajime, Hommura, Fumihiro, Honda, Ryoichi, Yokoo, Keiki, Fujita, Yuka, Oizumi, Satoshi, Morita, Ryo, Ikezawa, Yasuyuki, Tanaka, Hisashi, Kimura, Nozomu, Sasaki, Takaaki, Sukoh, Noriaki, Takashina, Taichi, Harada, Toshiyuki, Dosaka-Akita, Hirotoshi, Isobe, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632978/
https://www.ncbi.nlm.nih.gov/pubmed/34848786
http://dx.doi.org/10.1038/s41598-021-02561-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632978/
https://www.ncbi.nlm.nih.gov/pubmed/34848786
http://dx.doi.org/10.1038/s41598-021-02561-z

Ejemplares similares